Indications And Dose
Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures ▶BY MOUTH ▶Adult 18–69 years: Initially 5–10 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased gradually at intervals of at least 4 weeks ▶Adult (patients of Asian origin): Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased gradually at intervals of at least 4 weeks. ▶Adult 70 years and over: Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased gradually at intervals of at least 4 weeks Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures and who have risk factors for myopathy or rhabdomyolysis ▶BY MOUTH ▶Adult: Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased gradually at intervals of at least 4 weeks Severe primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients with high cardiovascular risk who have not responded adequately to diet and other appropriate measures (specialist use only) ▶BY MOUTH ▶Adult 18–69 years: Initially 5–10 mg once daily, then increased if necessary up to 40 mg once daily, dose to be increased gradually at intervals of at least 4 weeks ▶Adult (patients of Asian origin): Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased gradually at intervals of at least 4 weeks. ▶Adult 70 years and over: Initially 5 mg once daily, then increased if necessary up to 40 mg once daily, dose to be increased gradually at intervals of at least 4 weeks Severe primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients with high cardiovascular risk who have not responded adequately to diet and other appropriate measures, and who have risk factors for myopathy or rhabdomyolysis (specialist use only) ▶BY MOUTH ▶Adult: Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased gradually at intervals of at least 4 weeks Prevention of cardiovascular events in patients at high risk of a first cardiovascular event ▶BY MOUTH ▶Adult 18–69 years: 20 mg once daily ▶Adult (patients of Asian origin): Initially 5 mg once daily, then increased if tolerated to 20 mg once daily, dose to be increased gradually at intervals of at least 4 weeks. ▶Adult 70 years and over: Initially 5 mg once daily, then increased if tolerated to 20 mg once daily, dose to be increased gradually at intervals of at least 4 weeks Prevention of cardiovascular events in patients at high risk of a first cardiovascular event and with risk factors for myopathy or rhabdomyolysis ▶BY MOUTH ▶Adult: Initially 5 mg once daily, then increased if tolerated to 20 mg once daily, dose to be increased gradually at intervals of at least 4 weeks
Source pages 238, 239